Normalized claim
Quantified impact: 70% decrease
Potential 70% reduction in lithium required in sustainable batteries.
Last evidence check: Jul 22, 2026
MicrosoftEvidence: Medium55/100
1910 Genetics' transformative drug R&D
Use case typeDrug discoveryUpdated Jun 13, 2026
Microsoft and 1910 Genetics have initiated a five-year partnership to drive significant advancements in pharmaceutical research and development. The collaboration pairs Microsoft’s Azure Quantum Elements platform, designed for AI-driven scientific discovery, with 1910 Genetics' lab automation and multimodal AI expertise. The partnership seeks to address long-standing challenges in the pharmaceutical industry, including the high costs, extended timeframes, and limited success rates of drug development. This initiative aims to overhaul the traditional R&D pipeline, offering a transformative approach that reduces bottlenecks and introduces efficiency. By integrating AI, robotics, and HPC technologies, Microsoft and 1910 Genetics are catalyzing a shift towards faster and cost-effective drug discovery.
- Organization
- 1910 Genetics
- Industry
- Pharma
- Location
- United States
- Published
- February 2024
Reported outcomes
−70%
quantified impactOther quantified impact
Strategic outcomes
New business modelEnabled platform-as-a-service modelsSpeed & agilityAccelerated drug discovery cycleNew product / capabilityFaster screening of drug materialsInnovation & cultureTransformed traditional R&D pipeline
Why do we believe this?Outcome claims, sources, and evidence checks
Why do we believe this deployment?Customer identity, provider attribution, maturity, and source checks
- Customer
- 1910 Genetics
- Provider
- Microsoft
- Maturity
- Unknown
- Linked source
- azure.microsoft.com
No explicit deployment-stage evidence found.
Customer identity supportedSource describes one deploymentMaturity evidence evaluated
Primary read
Use case focus
Showing 2 of 2
- 1drug discovery enhancement
- 2AI-integrated platform deployment
- Pharmaceutical R&D increasingly costly – $2 billion per drug.
- Development timelines stretch over 12–15 years.
- Low success rate; <10% of new molecules pass FDA Phase 1 trials.
- Fragmented and disparate data impede effective drug design.
- Microsoft Azure Quantum Elements enhances computational chemistry.
- 1910 Genetics leverages robotics-driven lab automation.
- AI-driven acceleration of the drug discovery cycle.
- Integration enables Platform-as-a-Service (PaaS) models for researchers.
Technologies
- Potential 70% reduction in lithium required in sustainable batteries.
- Quick screening of 32 million drug materials via advanced AI.
- Overcoming 70 years of R&D productivity declines.
- Streamlined efforts against Alzheimer's, cancer, and infectious diseases.
Architecture
Drug discovery leverages interdisciplinary connectivity between 1910 Genetics' AI-driven data models and Microsoft Azure Quantum Elements' state-of-the-art AI cloud infrastructure. Robotics automates drug molecule testing with biologically diverse datasets simultaneously scaled via Platform-as-a-Service (PaaS) outreach.
Sources & evidence3
Evidence: Medium55/100Evidence strength
- Customer explicitly identified
- Quantified outcome available
- Technical implementation details available
- Multiple corroborating sources available
- Recent evidence check available
- Last evidence check: Jul 22, 2026.
Type: Blog PostPublished: Feb 29, 2024Publisher: azure.microsoft.comEvidence: VendorConfidence: Medium
AI-generated summary. Verify important details with the linked sources before relying on this case.
Explore related AI use cases
Customer evidence
Provider evidence
AI patterns
Browse the catalog
Was this useful?
Community
Comments
Loading comments...